Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$7.5M
Filings
59
Firms Hired
3
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
H.R. 10559 - LARC Access Expansion Act Contraceptive access
Client expense: $340,000 · Firm income: —
Matched citations: H.R. 10559
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $370,000 · Firm income: —
Matched citations: HR 5376
HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $220,000 · Firm income: —
Matched citations: HR 5376
Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
2024 · second_quarter · Firm: ORGANON & CO.
H.R.9029 - Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2025
Client expense: $220,000 · Firm income: —
Matched citations: H.R.9029
Water Affordability, Transparency, Equity, and Reliability Act of 2021
2024 · first_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Client expense: $370,000 · Firm income: —
Matched citations: HR 1352
Great Basin National Heritage Area and Mormon Pioneer National Heritage Area Extension Act
2024 · first_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Client expense: $370,000 · Firm income: —
Matched citations: H.R.2882
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars H.R.2882 - Further Consolidated Appropriations Act, 2024
Client expense: $370,000 · Firm income: —
Matched citations: HR 5376
Water Affordability, Transparency, Equity, and Reliability Act of 2021
2023 · fourth_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $500,000 · Firm income: —
Matched citations: HR 1352
HR 1352--Increasing Access to Biosimilars Act HR 5376 (117th Congress)--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $500,000 · Firm income: —
Matched citations: HR 5376
Water Affordability, Transparency, Equity, and Reliability Act of 2021
2023 · third_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $260,000 · Firm income: —
Matched citations: HR 1352
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $260,000 · Firm income: —
Matched citations: HR 5376
Water Affordability, Transparency, Equity, and Reliability Act of 2021
2023 · second_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $390,000 · Firm income: —
Matched citations: HR 1352
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $390,000 · Firm income: —
Matched citations: HR 5376
Water Affordability, Transparency, Equity, and Reliability Act of 2021
2023 · first_quarter · Firm: ORGANON & CO.
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $320,000 · Firm income: —
Matched citations: HR 1352
HR 1352--Increasing Access to Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health Biosimilars
Client expense: $320,000 · Firm income: —
Matched citations: HR 5376
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Client expense: $600,000 · Firm income: —
Matched citations: HR 2815
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Client expense: $600,000 · Firm income: —
Matched citations: HR 2855
Increasing Access to Biosimilars Act of 2021
2022 · fourth_quarter · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Client expense: $600,000 · Firm income: —
Matched citations: HR 2869
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Client expense: $600,000 · Firm income: —
Matched citations: HR 5376
Increasing Access to Biosimilars Act of 2021
2022 · fourth_quarter · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Inflation Reduction Act of 2022--Drug pricing/biosimilars Women's health
Client expense: $600,000 · Firm income: —
Matched citations: S. 1427
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Client expense: $280,000 · Firm income: —
Matched citations: HR 2815
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Client expense: $280,000 · Firm income: —
Matched citations: HR 2855
Increasing Access to Biosimilars Act of 2021
2022 · third_quarter · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Client expense: $280,000 · Firm income: —
Matched citations: HR 2869
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Client expense: $280,000 · Firm income: —
Matched citations: HR 5376
Increasing Access to Biosimilars Act of 2021
2022 · third_quarter · Firm: ORGANON & CO.
S. 1427--Increasing Access to Biosimilars Act HR 2869--Increasing Access to Biosimilars Act HR 2815--Bolstering Innovative Options to Save Immediately on Medicines Act HR 2855--Star Rating for Biosimilars Act HR 5376--Build Back Better Act--Drug pricing/biosimilars S Con Res 14--FY22 Budget Resolution--Drug pricing/biosimilars Women's health
Client expense: $280,000 · Firm income: —
Matched citations: S. 1427
Source: Senate LDA